Shares of Neos Therapeutics, Inc. (NASDAQ:NEOS) have been given a consensus rating of “Buy” by the seven analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $15.00.

Several research analysts have recently issued reports on NEOS shares. ValuEngine upgraded shares of Neos Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, May 18th. Zacks Investment Research upgraded shares of Neos Therapeutics from a “hold” rating to a “strong-buy” rating and set a $8.00 price objective for the company in a report on Wednesday, August 23rd. Finally, Cantor Fitzgerald started coverage on shares of Neos Therapeutics in a report on Monday, July 31st. They issued an “overweight” rating and a $20.00 price objective for the company.

Neos Therapeutics (NASDAQ NEOS) opened at 7.80 on Friday. Neos Therapeutics has a 12-month low of $4.85 and a 12-month high of $9.60. The company has a 50-day moving average price of $6.89 and a 200-day moving average price of $7.06. The firm’s market cap is $219.02 million.

Neos Therapeutics (NASDAQ:NEOS) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.83). The business had revenue of $4.91 million during the quarter. Neos Therapeutics had a negative net margin of 511.74% and a negative return on equity of 611.78%. On average, equities analysts predict that Neos Therapeutics will post ($3.22) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://theolympiareport.com/2017/08/28/analysts-set-neos-therapeutics-inc-neos-pt-at-15-00.html.

Hedge funds have recently added to or reduced their stakes in the stock. State of Wisconsin Investment Board acquired a new stake in Neos Therapeutics during the second quarter valued at approximately $102,000. OMERS ADMINISTRATION Corp acquired a new stake in Neos Therapeutics during the second quarter valued at approximately $110,000. Dynamic Technology Lab Private Ltd acquired a new stake in Neos Therapeutics during the second quarter valued at approximately $118,000. Mission Wealth Management LLC acquired a new stake in Neos Therapeutics during the first quarter valued at approximately $122,000. Finally, Tudor Investment Corp ET AL acquired a new stake in Neos Therapeutics during the second quarter valued at approximately $146,000. 44.29% of the stock is owned by institutional investors and hedge funds.

About Neos Therapeutics

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.